Product Images Toviaz

The text describes numerical data for the mean change from baseline in the number of times a person urinates in a 24-hour period. The data is represented visually in Figure 1, showing the changes by week and by treatment group for a study involving three different interventions: a placebo, a 4mg dose of Toviaz, and an 8mg dose of Toviaz.*

The text describes a clinical study that measures the change in urge incontinence episodes per 24 hours over a period of twelve weeks. The study includes three groups - a placebo group, a group taking Toviaz 4mg, and a group taking Toviaz 8mg. The results are visually presented in Figure 2.*

The text describes a figure (Figure 4) showing the change in urge incontinence episodes per 24 hours over the course of 12 weeks. The data represents a study including a placebo group and two groups taking different doses of the medication Toviaz. The mean change from baseline (initial measurement) is shown.*

The text is a brand name and company information for Pfizer Labs, which is a division of Pfizer Inc. located in New York City.*

This is a label of a product manufactured by Pfizer Labs, which is a division of Pfizer Inc. It is distributed by Pfizer and its location is in New York with the zip code 10017.*

This is a description of medication instructions for Toviaz, an extended-release tablet. The medication comes in a 4mg dosage and should be taken once daily, with or without food. It is important not to crush, chew or divide the tablet. The medication should be kept at a temperature between 20°to 25°C (68° to 77°F). The packaging includes a warning to keep the medication and all medicines out of the reach of children. Additional information from the full prescribing information and patient information is enclosed. The packaging also includes a statement that Toviaz is a professional sample and not for sale. Pfizer RxPathways™ is a program to help pay for Pfizer medicines which is mentioned on the packaging. The medication is made in Ireland.*

This is a prescription medication called Toviaz, with the active ingredient fesoterodine fumarate, that comes in 8 mg extended-release tablets. The recommended dose is one tablet per day, with or without food, and should not be crushed or chewed. The text includes a warning not to distribute the medication as it is a professional sample and not for sale. The rest of the text is unclear and might be a mixture of gibberish or non-English characters.*

This is a description for a medication called "Toviaz" which contains fesoterodine fumarate in extended release tablets. Each tablet contains 8 mg of the medication. The proper dosage and use instructions can be found in the accompanying prescribing information. The medication should be stored at around 20-25°C and protected from moisture, while being kept out of reach of children. This appears to be a professional sample and not intended for sale. The manufacturer of the medication is 1S, Pharmaceuticals, a subsidiary of Pfizer Inc. The rest of the text contains unreadable characters.*